Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
895.8 USD | -0.60% | -1.68% | +3.03% |
Apr. 17 | UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating | MT |
Apr. 17 | The market is pinning its hopes on earnings reports |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.03% | 96.84B | |
-3.08% | 102B | |
-1.11% | 21.48B | |
-18.33% | 20.82B | |
-8.03% | 18.6B | |
-40.70% | 16.81B | |
-26.85% | 13.78B | |
+1.28% | 13.4B | |
+21.32% | 11.06B | |
-19.36% | 8.88B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $765 From $775, Keeps Overweight Rating